logo-loader
AusCann Group Holdings Ltd

AusCann Group commences trading in the US increasing global exposure

The company aims to release its first medicinal cannabis products in FY2019.

men on the phone in an office
The cannabis sector in the US is gaining investor's attention

AusCann Group Holdings Ltd (ASX:AC8) (OTCQX:ACNNF) has commenced trading on the US OTCQX Market under the stock symbol ACNNF.

Trading on the OTCQX supports AusCann’s strategy to broaden its international investor base, particularly in North America where it has a number of strategic agreements in place.

The benefits of cross-trading in the US and expanded access to investors, diversification of the shareholder base, and enhancing the accessibility and liquidity of the company’s stock.

READ: Auscann Group makes steady progress towards production of cannabinoid medicines

AusCann’s managing director Elaine Darby said: “We believe the company will benefit significantly from the increased global exposure cross-trading will provide us and we look forward to strengthening our international partnerships.

“As regulatory changes are enacted worldwide and the benefits of cannabinoid medicines become more accepted, AusCann is seeing an increasing number of opportunities to expand its global footprint.”

AusCann aims to produce high quality, economical, and clinically validated cannabinoid medicines.

It has a vertically integrated strategy beginning with cultivation and production, through to manufacture and distribution of products.

This is made possible through a number of partnerships with industry leaders such as Canopy Growth Corp and Fundacion Daya.

The company is initially targeting medications for neuropathic and chronic pain in Australia and internationally, a market estimated to be worth $9 billion in Australia alone.

Quick facts: AusCann Group Holdings Ltd

Price: $0.36

Market: ASX
Market Cap: $114.14 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of AusCann Group Holdings Ltd named herein, including the promotion by the Company of AusCann Group Holdings Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Auscann targeting pain management with Australian cannabinoid products

Elaine Darby, managing director of Auscann Group Holdings Ltd (ASX:AC8), spoke to Proactive Investors at the ASX Small and Mid-Cap Conference in Sydney. Auscann is continuing to make steady progress towards releasing its first medicinal cannabis products during the financial year 2019....

on 09/05/2018

2 min read